Item 8.01. Other Events.

Story continues below

As previously announced, on June 30, 2017, Opexa Therapeutics, Inc., a Texas corporation (“Opexa”), Opexa Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Opexa (“Merger Sub”), and Acer Therapeutics Inc., a Delaware corporation (“Acer”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Acer, with Acer becoming a wholly-owned subsidiary of Opexa and the surviving corporation of the merger (the “Merger”).

Also as previously announced, on September 19, 2017 at 9:00 a.m. Pacific Time, Opexa will hold a special meeting of its shareholders to vote upon the Merger and related proposals as set forth in Opexa’s proxy statement/prospectus/information statement for the special meeting, dated August 11, 2017, a copy of which has been provided to Opexa’s shareholders of record as of August 9, 2017.

On September 11, 2017, Opexa issued a press release announcing that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis) have both recommended that Opexa shareholders vote “FOR” the Merger and the related proposals in the Company’s proxy statement/prospectus/information statement referred to above. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

Reference is made to the Exhibit Index included with this Current Report on Form 8-K.

Opexa Therapeutics, Inc. Exhibit
EX-99.1 2 opxa_ex991.htm PRESS RELEASE Blueprint   Exhibit 99.1   Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Opexa Therapeutics   Shareholders Vote “FOR” the Proposed Merger and Related Proposals     THE WOODLANDS,…
To view the full exhibit click here


Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its T-cell technology. The Company’s product candidates include Tcelna and OPX-212. Tcelna is an autologous T-cell immunotherapy that is being developed for the treatment of secondary progressive MS (SPMS) and is tailored to each patient’s immune response profile to myelin. Tcelna is designed to reduce the number and/or functional activity of specific subsets of myelin-reactive T-cells (MRTCs) known to attack myelin. Tcelna is manufactured using its method for the production of an autologous T-cell product. In addition to the ongoing clinical development of Tcelna, the Company is developing OPX-212 as an autologous T-cell immunotherapy for the treatment of NMO.

An ad to help with our costs